Castration-resistant prostate cancer (CRPC) is prostate cancer that continues to grow even after treatments that reduce testosterone to very low levels. Normally, prostate cancer cells depend on testosterone to fuel their growth, so cutting off that supply (called androgen deprivation therapy, or ADT) slows the disease. In CRPC, the cancer has found ways to keep growing despite testosterone levels being suppressed below 50 ng/dL, which is the threshold considered “castrate level.” This shift marks a more aggressive phase of the disease that requires different treatment strategies.
How CRPC Is Diagnosed
A CRPC diagnosis requires two things happening at once: testosterone remains suppressed at castrate levels (below 50 ng/dL), and the cancer is showing signs of progression. Progression is typically measured through rising PSA, a protein produced by prostate cells. Specifically, doctors look for a PSA increase of more than 25% across two consecutive blood draws taken at least one week apart, with the absolute PSA level above 2.0 ng/mL. Progression can also show up as new tumors on imaging or growth of existing ones.
The 50 ng/dL testosterone threshold was established over 40 years ago and remains the standard used in clinical guidelines and trials. Some research suggests that outcomes improve when testosterone is driven even lower, below 20 ng/dL, but that stricter cutoff has not yet replaced the traditional one in practice.
Why the Cancer Stops Responding
The shift to castration resistance isn’t random. Prostate cancer cells adapt at the molecular level, finding alternative ways to activate the androgen receptor, the protein that testosterone normally switches on to drive cell growth. Several mechanisms are at work, sometimes simultaneously.
One common adaptation involves mutations in the androgen receptor itself. Over 100 such mutations have been identified. Some make the receptor respond to weaker hormones produced by the adrenal glands. Others are particularly problematic because they convert anti-cancer drugs into molecules that actually stimulate the receptor, essentially turning the treatment into fuel. These mutations are rare in early prostate cancer but appear in roughly 10 to 30% of patients whose cancer has become castration-resistant after initial hormone therapy.
Perhaps the most important discovery has been shortened versions of the androgen receptor called splice variants. The most common one, known as AR-V7, is missing the section of the receptor that current hormone-blocking drugs target. Because of this, it stays permanently “on” regardless of treatment. AR-V7 levels can actually increase in response to newer hormone therapies, which helps explain why some patients stop responding to those drugs. This finding has driven research into therapies that target a different part of the receptor entirely.
Non-Metastatic vs. Metastatic CRPC
CRPC is divided into two categories based on whether the cancer has visibly spread beyond the prostate. Non-metastatic CRPC (nmCRPC) means PSA is rising despite castrate testosterone levels, but standard imaging like CT scans and bone scans show no detectable spread. Metastatic CRPC (mCRPC) means the cancer has visibly spread to bones, lymph nodes, or other organs.
The distinction matters for treatment decisions, but it’s also somewhat blurry. A study using a newer, more sensitive type of scan called PSMA-PET found that 98% of patients classified as non-metastatic on conventional imaging actually had detectable disease: 44% had cancer in the pelvic area and 55% had distant spread. In other words, most patients labeled as nmCRPC on standard scans would be reclassified as metastatic if scanned with more advanced technology.
For patients with nmCRPC, the speed at which PSA doubles is a key predictor of how quickly the disease will progress. A PSA doubling time of 10 months or less signals high risk. Without additional treatment, the median time before detectable metastases appear ranges from 25 to 30 months in nmCRPC patients. Those with rapid PSA doubling times are eligible for newer androgen receptor inhibitors that have been shown to delay disease spread and extend survival.
How PSMA-PET Scans Changed Detection
Traditional imaging has significant limitations in finding prostate cancer that has spread, particularly at low PSA levels. CT and MRI detect lymph node metastases with a sensitivity of only 30 to 80%, and older PET scan techniques using choline-based tracers have just a 19% chance of finding disease when PSA is below 1.0 ng/mL.
PSMA-PET scans, which target a protein found on the surface of most prostate cancer cells, perform substantially better. In head-to-head comparisons, PSMA-PET detected cancerous lesions at a rate of 86.5% versus 70.3% for older PET technology. The gap widens at low PSA levels: when PSA was below 0.5 ng/mL, PSMA-PET found disease in 50% of patients compared to just 12.5% with choline-based scans. This improved sensitivity means cancers that would have gone undetected for months or years can now be identified and treated earlier.
Treatment for Non-Metastatic CRPC
Patients with nmCRPC who have a PSA doubling time of 10 months or less are typically treated with one of three androgen receptor inhibitors (enzalutamide, apalutamide, or darolutamide) added on top of their ongoing ADT. Clinical trials showed that all three significantly extended the time before metastases developed compared to ADT alone. The goal at this stage is to delay the cancer’s spread for as long as possible while maintaining quality of life.
Treatment for Metastatic CRPC
Once CRPC has visibly spread, the treatment landscape expands considerably. The first survival-extending therapy for mCRPC, approved in 2004, was the chemotherapy drug docetaxel. Since then, multiple additional options have become available, and sequencing them effectively has become a central challenge in managing the disease.
Androgen receptor signaling inhibitors like abiraterone and enzalutamide work by blocking the cancer’s ability to use even trace amounts of hormones. However, because many of these drugs are now used earlier in the disease course (during the castration-sensitive phase), patients who progress to mCRPC may have already exhausted these options, narrowing what’s available next.
Targeted Therapy Based on Genetics
About 20 to 25% of men with mCRPC carry mutations in DNA repair genes, most notably BRCA1 and BRCA2. These mutations make cancer cells vulnerable to a class of drugs called PARP inhibitors, with olaparib being the most established. PARP inhibitors work by exploiting the cancer cell’s inability to repair its own DNA, causing the cells to die. Genetic testing of the tumor has become an important step in mCRPC care because it determines whether this targeted approach is an option.
Radioligand Therapy
For patients whose cancer has progressed through both hormone-blocking drugs and chemotherapy, a newer option targets cancer cells with targeted radiation delivered through the bloodstream. Lutetium-177-PSMA-617, approved by the FDA in March 2022, binds to the PSMA protein on cancer cells and delivers radiation directly to the tumor sites. In the pivotal trial that led to approval, patients who received this therapy lived a median of 15.3 months compared to 11.3 months with standard care alone. To qualify, patients need at least one PSMA-positive lesion on a PET scan and must have already been treated with at least one androgen receptor inhibitor and one or two rounds of chemotherapy.
Survival and Prognosis
Survival with mCRPC has improved meaningfully over the past two decades as new therapies have been layered in. A large retrospective analysis of over 4,400 patients treated in community urology settings found a median overall survival of 44 months from the start of treatment. Among those patients, 28% were still alive at the five-year mark, and those long-term survivors had a median survival of 97 months (just over eight years). These numbers reflect the growing reality that while mCRPC remains a serious diagnosis, many patients live considerably longer than the historical averages suggested.
Long-Term Effects of Sustained Hormone Suppression
Because CRPC treatment requires continued suppression of testosterone, often for years, the cumulative side effects of that suppression become an important part of living with the disease. A large study comparing men on ADT to those not receiving it found elevated risks across several categories. Bone fractures carried the highest increased risk (39% higher than men not on ADT), followed by diabetes (21% higher), dementia (16% higher), coronary heart disease (12% higher), and heart attack (11% higher). The risks for fractures and diabetes increased in a dose-dependent pattern, meaning the more ADT a patient received, the higher the risk climbed.
These side effects mean that managing CRPC involves more than just fighting the cancer. Bone density monitoring, blood sugar management, cardiovascular health, and cognitive awareness all become part of the ongoing care picture. Exercise, calcium and vitamin D supplementation, and regular metabolic screening are common components of a comprehensive management plan for men on long-term ADT.